Last $9.77 USD
Change Today -0.09 / -0.91%
Volume 59.0K
As of 8:10 PM 08/21/14 All times are local (Market data is delayed by at least 15 minutes).

syneron medical ltd (ELOS) Snapshot

Open
$9.82
Previous Close
$9.86
Day High
$9.88
Day Low
$9.71
52 Week High
01/16/14 - $13.32
52 Week Low
09/6/13 - $8.04
Market Cap
345.2M
Average Volume 10 Days
30.6K
EPS TTM
$0.16
Shares Outstanding
35.3M
EX-Date
--
P/E TM
61.0x
Dividend
--
Dividend Yield
--
Current Stock Chart for SYNERON MEDICAL LTD (ELOS)

syneron medical ltd (ELOS) Related Businessweek News

No Related Businessweek News Found

syneron medical ltd (ELOS) Details

Syneron Medical Ltd., together with its subsidiaries, engages in the research, manufacture, development, marketing, and sale of aesthetic medical products worldwide. The company develops products based on its proprietary Electro-Optical Synergy (ELOS) technology, which uses the synergy between electrical energy and optical energy to provide aesthetic medical treatments. Its products target a range of non-invasive aesthetic medical procedures, including hair removal, wrinkle reduction, rejuvenation of the skin’s appearance through the treatment of superficial benign vascular and pigmented lesions, acne treatment, treatment of leg veins, treatment for the temporary reduction in the appearance of cellulite and thigh circumference, ablation and resurfacing of the skin, laser-assisted lipolysis, and topical skin brightening products. It also develops, manufactures, and markets non-invasive technologies for fat cell destruction and body sculpting; and Viador system, a handheld device with a radiofrequency-needle array for use in transdermal delivery of biologic drug-products via a system-specific skin patch. The company sells its products to dermatologists, plastic and cosmetic surgeons, other qualified practitioners, and aestheticians and medical spas through direct sales force and distributors; and to home-use consumers directly, as well as through retailers and a chain of distributors. Syneron Medical Ltd. was founded in 2000 and is headquartered in Yokneam Illit, Israel.

syneron medical ltd (ELOS) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

syneron medical ltd (ELOS) Key Developments

Syneron Medical Introduces New FDA-Cleared 5mm Spot Size for Treatment of Onychomycosis

Syneron Medical Ltd. announced the market launch of its proprietary handpiece featuring a new 5-millimeter spot size for the Gentle Pro Nd:YAG Laser Series. The introduction of this new FDA-cleared handpiece expands the functionality of the GentleYAG(R) Pro and GentleMax(R) Pro Nd:YAG laser to treat onychomycosis (nail fungus) in addition to its existing capabilities for hair removal and for the treatment of vascular and pigmented lesions. Onychomycosis is one of the most commonly diagnosed foot conditions, affecting 10%-12% of the population. This prevalent and persistent disorder results in thick, jagged nails that can injure surrounding skin, spawning secondary infections and ulcers. Diabetics are especially at risk with a 34% chance of developing fungal nail infection and an increased instance of other complications. In those age 70 and up, 50% are expected to develop onychomycosis. Currently a $1.6 billion market in the United States, the treatment of nail fungus has been challenging. The previous standard of care has been oral antifungal medications, which carry side effects including the potential for hepatotoxicity (chemical driven liver damage) and a high failure rate. Topical treatments have also resulted in limited success due to their inability to properly penetrate the nail. Laser therapies like Candela's Gentle Pro Nd:YAG Laser allow physicians to treat onychomycosis symptoms locally without the systemic effects of oral medications. All infectious agents, except prions, can be killed by heat, which makes laser therapy an extremely promising new option for onychomycosis sufferers. With its precision 5 mm handpiece, the Gentle Pro Nd:YAG Laser raises the temperature under the nail to a level that's inhospitable to fungus in order to increase the appearance of clear nails.

Syneron Medical Ltd. Announces Unaudited Consolidated Financial Results for the Second Quarter and Six Months Ended June 30, 2014; Reports Impairment of Intangible Assets

Syneron Medical Ltd. announced unaudited consolidated financial results for the second quarter and six months ended June 30, 2014. For the quarter, the company reported revenue of $64.618 million against $68.765 million a year ago. Operating loss was $0.145 million against $4.636 million a year ago. Income before tax was $0.083 million against loss before tax benefit of $4.783 million a year ago. Loss attributable to shareholders was $0.434 million or $0.01 per diluted share against $4.348 million or $0.12 per diluted share a year ago. Non-GAAP operating income was $3.158 million against $1.115 million a year ago. Non-GAAP net income attributable to shareholders was $2.486 million or $0.07 per diluted share against $0.691 million or $0.02 per diluted share a year ago. The increase in revenue was the result of growth in the North American, EMEA and APAC regions, partially offset by lower revenue in the LATAM region. The company generated $3.7 million in cash from operations. For the six months, the company reported revenue of $121.431 million against $129.969 million a year ago. Operating loss was $0.951 million against $7.236 million a year ago. Loss before tax was $0.559 million against loss before tax benefit of $7.611 million a year ago. Loss attributable to shareholders was $1.526 million or $0.04 per diluted share against $6.791 million or $0.19 per diluted share a year ago. Net cash used in operating activities was $0.740 million against $11.902 million a year ago. Purchases of property and equipment were $0.936 million against $2.591 million a year ago. Non-GAAP operating income was $5.049 million against $1.983 million a year ago. Non-GAAP net income attributable to shareholders was $3.814 million or $0.10 per diluted share against $1.323 million or $0.04 per diluted share a year ago. For the quarter, the company reported other non-recurring costs of $1.2 million, mainly related to impairment of intangible assets.

Syneron Receives CFDA Clearance for elure(TM) Advanced Skin Brightening Lotion

Syneron Medical Ltd. announced that it has received the China Food and Drug Administration (CFDA) clearance for its elure(TM) Advanced Skin Brightening Lotion. The elure skin brightening solution is a new cosmetic product originally available only from dermatologists, plastic surgeons and other medical aesthetic providers. Based on a proprietary and unique formulation, elure Advanced Skin Brightening Lotion has been shown to act rapidly and safely. In a clinical study conducted at Peking University First Hospital, a statistically significant improvement in skin tone evenness, overall fairness and brightness was observed as early as Day 7 following the start of treatment, based on quantified measurements and dermatologist assessment. In clinical studies conducted in China, Korea and the United States, elure Advanced Skin Brightening Lotion, with its unique formulation, showed a statistically significant improvement in overall skin appearance, with visible results in as fast as 7-8 days. This improvement, as scientifically measured, included diminishing the appearance of discoloration while correcting uneven skin tone to reveal a brighter, more glowing complexion.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ELOS:US $9.77 USD -0.09

ELOS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ELOS.
View Industry Companies
 

Industry Analysis

ELOS

Industry Average

Valuation ELOS Industry Range
No financial data is available for ELOS.
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SYNERON MEDICAL LTD, please visit www.syneron.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.